Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGM2 | P21980 | 1/20 | 0.54 |
| ▸ | NT5E | P21589 | 1/20 | 0.53 |
| ▸ | FUT5 | Q11128 | 1/20 | 0.51 |
| ▸ | KRAS | P01116 | 5/20 | 0.49 |
| ▸ | HINT1 | P49773 | 3/20 | 0.49 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.49 |
| ▸ | IMPDH1 | P20839 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | STING1 | Q86WV6 | 2/20 | 0.47 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.47 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.47 |
| ▸ | P2RY2 | P41231 | 1/20 | 0.47 |
| ▸ | P2RY4 | P51582 | 1/20 | 0.47 |
| ▸ | P2RY6 | Q15077 | 1/20 | 0.47 |
| ▸ | DCPS | Q96C86 | 1/20 | 0.46 |
| ▸ | GSK3A | P49840 | 1/20 | 0.45 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.45 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1506529 | 0.93 | NT5E (0.56) | TGM2NT5EFUT5KRASHINT1 | |
| SCHEMBL237754 | 0.83 | HINT1 (0.58) | TGM2NT5EKRASHINT1STING1 | |
| Guanosine SCHEMBL9827513 | 0.80 | NT5E (0.69) | TGM2NT5EFUT5KRASHINT1 | |
| Guanosine SCHEMBL6066347 | 0.80 | NT5E (0.69) | TGM2NT5EFUT5KRASHINT1 | |
| Guanosine SCHEMBL30589987 | 0.80 | NT5E (0.69) | TGM2NT5EFUT5KRASHINT1 | |
| SCHEMBL23477431 | 0.79 | NT5E (0.70) | TGM2NT5EFUT5KRASHINT1 | |
| Guanosine SCHEMBL30125158 | 0.79 | NT5E (0.68) | TGM2NT5EFUT5KRASHINT1 | |
| Guanosine SCHEMBL19211836 | 0.79 | NT5E (0.68) | TGM2NT5EFUT5KRASHINT1 | |
| Guanosine SCHEMBL4625995 | 0.79 | NT5E (0.68) | TGM2NT5EFUT5KRASHINT1 | |
| SCHEMBL309061 | 0.79 | TGM2 (0.55) | TGM2NT5EFUT5KRASHINT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9067964-B2 | Complex and method for enhancing nuclear delivery | OLIGOMER SCIENCES AB (SE) | 2015-06-30 | — | — | US | disclosed |
| US-20110306138-A1 | COMPLEX AND METHOD FOR ENHANCING NUCLEAR DELIVERY | OLIGOMER SCIENCES AB (SE) | 2011-12-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110306138-A1 | COMPLEX AND METHOD FOR ENHANCING NUCLEAR DELIVERY | SNRPE, SNRPA, HNRNPH3 | TGM2 1855/4885NT5E 390/4885FUT5 1989/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.